



The United Laboratories International Holdings Limited

Receives the 3rd Capital Outstanding China Enterprise Award

(16 May 2008 – Hong Kong) – The United Laboratories International Holdings Limited (“TUL” or the “Group”; Stock code: 3933), one of the leading manufacturers of antibiotics in the PRC, received the 3rd Capital Outstanding China Enterprise Award.

At the award presentation ceremony, Mr. Choy Kam Lok, Chairman of TUL, said “We are pleased to be granted the 3rd Capital Outstanding China Enterprise Award. This accolade does not only represent the widespread recognitions of TUL’s capability from different aspects in society, but also demonstrates our leading position in the pharmaceuticals manufacturing industry. TUL has always been dedicated to pushing forward the development of the pharmaceuticals manufacturing industry in China and providing the public with a diversified selection of quality medicines made by our cutting-edge technology for pharmaceutical manufacturing. With the accelerated reform to the medical system propelled by the PRC government recently including the increase of the contributions for medical insurance and expanding coverage in the medical insurances in both urban and rural areas, we strongly believe that the pharmaceutical market in China has promising prospect. Looking forward, we will further optimize our production capacity and maximize the economy of scale. We will also strengthen our ability in research and development in order to develop more quality medicines so as to capture the immense business opportunities arising from robust demand for quality medicines in the market.”

【Photo】



Caption: At the ceremony, Hon Wong Ting-kwong, BBS, Legislative Council member in Hong Kong, presents the Outstanding China Enterprise Award to Mr. Choy Kam Lok, Chairman of TUL.

- End -

Company Background

Listed on the Stock Exchange of Hong Kong in June 2007, **TUL** is one of the major manufacturers of antibiotic products in China and principally engaged in the manufacturing and selling of bulk medicine and intermediate products used to produce antibiotics, and also antibiotics as finished goods. The Group also produces and sells, in smaller amounts, cough syrup, anti-allergy medicine as well as empty capsule casings. As of 31 December 2007, the Group has a total of 150 products qualified to produce in the PRC and/Hong Kong based on the Drug Registration Approvals in the PRC and Certificates of Drug or Product Registration in Hong Kong, including 31 bulk medicines and 119 finished products.

For further enquiries, please contact
iPR Ogilvy Ltd.

Sandy Yeung/ Stephanie Yuen / Tina Law / Callis Lau
Tel: (852) 2136 8072/ 3170 6609/ 2136 6181/ 2136 6952
Fax: (852) 3170 6606
E-mail: sandy.yeung@iprogilvy.com/ stephanie.yuen@iprogilvy.com/
tina.law@iprogilvy.com/ callis.lau@iprogilvy.com